StockWatch
·

Wellgistics Health, Inc. Q3 FY26 Results

WGRXQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue2.6750.0%11.3%
Total Income2.6750.0%11.3%
Expenditure6.0433.8%82.5%
PBT10.54157.4%130.7%
Net Profit10.59157.7%130.9%
OPM—
NPM100.00%
EPS3.29146.1%815.2%
View full financials

DataMEDS AI Reports Q3 2026 Revenue of $2.7 Million, Up 50% Sequentially, and Net Profit Per Share of $2.72

14 Nov 2026 · 14 Nov, 2:52 am

Summary

DataMEDS AI reported a 50% sequential revenue growth in the third quarter of 2026, with revenue reaching $2.7 million. The company achieved a net profit per share of $2.72. Management highlighted the strong performance driven by Corexa Pharmacy and the strategic addition of new revenue streams including medical foods, diagnostic lab tests, and compounded peptides. The company also noted the positive impact of new partnerships and acquisitions, positioning DataMEDS AI for continued growth.

Key Highlights

  1. 1

    Third quarter 2026 revenue reached $2.7 million, marking a significant 50% increase from the second quarter of 2026.

  2. 2

    The company reported a net profit per share of $2.72 for the third quarter of 2026.

  3. 3

    Corexa Pharmacy drove a 50% sequential increase in revenue, with continued growth anticipated in the fourth quarter.

  4. 4

    The launch of the Health Lives Here mobile app, in partnership with the NFL Alumni Health marketing platform, provides a new customer acquisition channel for Corexa Pharmacy.

  5. 5

    An exclusive license for the REBOOT GLP-1 patient management platform was secured, aimed at scaling customer acquisition and increasing long-term customer value.

  6. 6

    The acquisition of Helomics cancer diagnostics laboratory adds an incremental proprietary revenue stream and opens opportunities in the cancer pharmaceuticals market.

  7. 7

    DataMEDS AI regained full compliance with Nasdaq listing standards in October 2026.

Management Comments

G

Gerald Commissiong

Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions. Health Lives Here, backed by NFL Alumni Health, brings patients to Corexa Pharmacy. The REBOOT license gives us patented, AI-assisted tools to keep GLP-1 patients engaged, proprietary Tollo Health medical foods for muscle loss associated with weight loss therapies gives them unique tools to mitigate the drugs’ side effects and Helomics adds diagnostic testing revenue streams. With our first HMO relationship and compounded peptides opening new channels, and full Nasdaq compliance restored, we believe DataMEDS is well positioned for continued growth going forward.

Informational and educational content only. Not investment advice.